Sales reps: footsoldiers in drug company wars

Prescrire’s sales reps monitoring network has existed for 13 years. Successive annual reports show no major changes in reps’ practices (a)(1,2), but a number of new trends were reported last year.

**Virtually no new substance presented to community practitioners.** In 2003 most reps seen by network members promoted either old drugs or their variants (isomers, metabolites, combinations, and me-too) (b). Most other products were new formulations (orally dispersible tablets are trendy) or new dose strengths. These trends reflect the type of new pharmaceuticals we described in “2003: the year in review” (issue 70 on page 71). New indications for old drugs are welcome as long as they are based on thorough long-term evaluation. However, 25% of indications promoted in 2003 conflicted with the SPCs.

**Near-extinction of Commission de la transparence.** What prescribers want most from sales reps is comparative data and clinical information, according to a recent American survey, in which only 35% of prescribers found rep visits useful (3,4).

**Risks barely mentioned.** Contraindications were mentioned by only one-third of reps who visited network members, but the information was incomplete in about 50% of visits. Information on interactions and adverse effects was just as scant.

Reports by the Commission de la transparence [editor’s note: official opinion on added therapeutic value] are one source of comparative information that sales reps in France are legally obligated to show health professionals. Yet, according to Prescrire’s network, only 1% of reps spontaneously offered this document in 2003. Worse, when network members (who remain anonymous) asked for the report, most reps said they do not have it and some didn’t even know what it was! Some reps do use these official measures of the advantage offered by a new drug relative to existing options, especially when it allows them to criticise their competitors’ products. Other reps deliberately maintain prescribers’ confusion between the terms ‘added therapeutic value’ and ‘therapeutic value’. A me-too, for instance, can have a high therapeutic value, without offering any advantages over existing products.

When network members asked reps about the adverse effects of older drugs, many reps said they assumed the risks were well known. But if this were the case, would there be any need to recall these products’ beneficial effects?! Failure to point out adverse effects is especially serious given the current tendency to encourage health professionals to prescribe higher doses, for longer periods, and in borderline indications (5).

**Better sales training?** Biased data are all the more harmful when they are cleverly presented, and sales reps seen by network members last year appeared to have honed their selling skills. Following reps’ visits, its observers said they found their arguments convincing in about 20% of cases, compared to 9% the year before, and 6% the year before that (2).

This ‘improvement’ might be due to new methods used by drug companies and their business partners, including sophisticated analysis of prescriber behaviour during rep visits and better use of computers (6,7). Or it might simply be due to an increase in human and financial resources? According to the president of the French pharma industry (LEEM), the number of sales reps operating in France has increased by 40% over the last decade, to 23,000 at present (8).

The figures on launch campaigns that were made public are extremely impressive. For example, AstraZeneca claimed they spent a billion US dollars on the international launch of their statin rosuvastatin, which competes with Pfizer’s productator-

---

**Preclinical editorial staff** “Sales representatives, a damming report by Prescrire reps monitoring network” Prescrire Int 1999; 8 (41); 86-89.
3-“Do old detailing methods need an overhaul?” Scrip 2003; (2872): 16.
6-“Improving rep visits with ‘closed loop’ marketing” Scrip 2003; (2872): 16.
7-Golangelo R “Physicians’ attitudes to online detailing explored” Scrip 2003; (2867): page 6.
9-“Pfizer rises early to the challenge of Crestor” Scrip 2003; (2876): 7.
11-Pelegry M - Pfizer Executive Vice President, quoted in: JH “La qualité de la visite médicale” Visite Actuelle 2003; (96): 14.

---

Selected references from Prescrire document watch.
1-Prescrire Editorial Staff “Sales representatives, a damming report by Prescrire reps monitoring network” Prescrire Int 1999; 8 (41); 86-89.
3-“Do old detailing methods need an overhaul?” Scrip 2003; (2872): 16.
4-Sanforche C “MG et VM: ’Je t’aime, moi non plus’” Le Généraliste 2003; (2262): 22-25.
6-“Improving rep visits with ‘closed loop’ marketing” Scrip 2003; (2872): 16.
7-Golangelo R “Physicians’ attitudes to online detailing explored” Scrip 2003; (2867): page 6.
9-“Pfizer rises early to the challenge of Crestor” Scrip 2003; (2876): 7.
11-Pelegry M - Pfizer Executive Vice President, quoted in: JH “La qualité de la visite médicale” Visite Actuelle 2003; (96): 14.

---

Translated from Rev Prescrire February 2004; 24 (247): 104

Get away!